Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAALAD2 | Q9Y3Q0 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 8/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.45 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603169 | 0.91 | NAALAD2 (0.51) | NAALAD2TBXAS1FOLH1GPR132MMP9 | |
| SCHEMBL4198783 | 0.89 | GPR132 (0.52) | TBXAS1FOLH1NAPRTGPR132MMP9 | |
| SCHEMBL29561216 | 0.89 | OPRK1 (0.48) | TBXAS1SLC15A1MMP9MMP8MMP12 | |
| SCHEMBL30685124 | 0.88 | MME (0.50) | TBXAS1NAPRTGPR132MMP9MMP8 | |
| SCHEMBL30019030 | 0.87 | ERAP2 (0.48) | FOLH1GPR132 | |
| SCHEMBL29383060 | 0.86 | MME (0.49) | TBXAS1NAPRTGPR132 | |
| SCHEMBL29413325 | 0.86 | MME (0.49) | TBXAS1NAPRTGPR132 | |
| SCHEMBL3048908 | 0.86 | NAALAD2 (0.68) | NAALAD2POLBFOLH1SLC15A1 | |
| SCHEMBL6236774 | 0.86 | NAALAD2 (0.68) | NAALAD2POLBFOLH1SLC15A1 | |
| SCHEMBL3048911 | 0.86 | NAALAD2 (0.68) | NAALAD2POLBFOLH1SLC15A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRAS S.A. (GR) | 2025-06-12 | — | — | US | claimed |
| CN-119060201-A | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-12-03 | — | — | CN | claimed |
| CN-111757891-B | Chemo-enzymatic synthesis of Soxhlet Ma Lutai, liraglutide and GLP-1 | 费森尤斯卡比有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-111819191-B | Chemoenzymatic synthesis of liraglutide, soxhlet Ma Lutai and GLP-1 | 费森尤斯卡比有限公司 | 2024-08-20 | — | — | CN | claimed |
| CN-112912390-B | GLP-1 analogues and methods of preparation | 北京费森尤斯卡比医药有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117098843-A | Subtilisin variants and uses thereof | 费森尤斯卡比有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-20230131339-A1 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | BADEN-WUERTTEMBERG STIFTUNG GGMBH (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4110790-A2 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | Universität Ulm (DE) | 2023-01-04 | — | — | EP | claimed |
| EP-3864032-B1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | FRESENIUS KABI IPSUM S R L (IT) | 2022-11-30 | — | — | EP | claimed |
| CN-114790236-A | Synthetic method of GCGR/GLP-1R double-target-point agonist polypeptide | 深圳市图微安创科技开发有限公司 | 2022-07-26 | — | — | CN | claimed |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-07-26 | — | — | US | claimed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | claimed |
| US-12497644-B2 | Subtilisin variants and their use | Fresenius Kabi Ipsum S.R.L. (IT) | 2025-12-16 | — | — | US | disclosed |
| EP-4291647-B1 | SUBTILISIN VARIANTS AND THEIR USE | FRESENIUS KABI IPSUM S R L (IT) | 2025-06-18 | — | — | EP | disclosed |
| WO-2025094036-A1 | A PROCESS FOR THE PREPARATION OF LIRAGLUTIDE | PIRAMAL PHARMA LIMITED (IN) | 2025-05-08 | — | — | WO | disclosed |
| CN-119391659-A | Polypeptide ligase mutant and preparation method of polypeptide | 天津凯莱英生物科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-113150108-B | Solid-phase synthesis method of liraglutide | 台州吉诺生物科技有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-113621046-B | Use and method of polymer anion exchange filler in preparation of liraglutide | 重庆宸安生物制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-110191892-B | Alanine-lysine-glutamic acid tripeptide derivative and application thereof | 深圳市健元医药科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041680-A1 | PROCESS FOR THE MANUFACTURE OF GLP-1 ANALOGUES | GLP1R, IAPP, VIP | NAALAD2 924/4885POLB 1761/4885TBXAS1 1259/4885 |
| US-11396533-B2 | Process for the manufacture of GLP-1 analogues | GLP1R, IAPP, VIP | NAALAD2 924/4885POLB 1761/4885TBXAS1 1259/4885 |
| US-20250188115-A1 | PROCESS FOR PREPARING A GLUCAGON-LIKE PEPTIDE | GLP1R, IAPP, GCG | NAALAD2 218/4885POLB 3697/4885TBXAS1 2617/4885 |
| US-20230131339-A1 | EPI-X4 BASED PEPTIDES AND DERIVATIVES THEREOF | CXCR4, SDF4, ACKR3 | NAALAD2 741/4885POLB 3828/4885TBXAS1 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.